A-Seeds is a biotech company developing regenerative medicines that leverage stem cell therapy and gene editing techniques to enhance tissue regeneration in cancer patients. The company aims to improve patient outcomes by minimizing the side effects associated with traditional cancer treatments.
Funding
$3.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer patients face limited treatment options, and traditional cancer treatments often come with significant side effects that can negatively impact patient outcomes and quality of life. There is a need for more effective and less toxic therapies, particularly for cancers with limited treatment options.
Solution
A-Seeds is developing regenerative medicines using stem cell and gene-editing technologies, specifically non-viral gene-modified immune cell therapy, to target and eliminate cancer cells while minimizing harm to healthy tissues. Their approach aims to enhance tissue regeneration and improve patient outcomes by providing effective treatments for cancers with limited therapeutic options. The company focuses on translating academic research into clinical applications, with the goal of delivering innovative therapies to patients in need. A-Seeds' lead product, AP8901, is an EPHB4 CAR-T cell therapy product, which has completed its first-in-human dosing.
Target Audience
The primary target audience includes cancer patients with limited treatment options, oncologists, and medical researchers focused on regenerative medicine and immunotherapy.
Features
- Non-viral gene modification technology for enhanced safety and efficacy
- CAR-T cell therapy targeting specific cancer antigens
- Focus on regenerative medicine to repair damaged tissues
- Pipeline of novel CAR-T products
- Collaboration with academic institutions and industry partners